Abstract: Compounds and a method for imaging myocardial perfusion, including administering to a patient a compound linked to an imaging moiety, wherein the compound binds MC-1, and scanning the patient using diagnostic imaging. Kits including the compound or precursor compounds linked or not linked to an imaging moiety are also described.
Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.
Abstract: A method of preparing radioisotope hybrid nanocomposite particles using a sol-gel reaction, and radioisotope hybrid nanocomposite particles prepared using the same are provided. The method includes preparing a complex precursor using a metal ion and an unshared electron pair reactive compound, growing hybrid nanocomposite particles based on the complex precursor by means of a sol-gel reaction, calcining the nanocomposite particles in the air to remove organic matters present in the nanocomposite particles, and irradiating the nanocomposite particles with neutrons to prepare radioisotope hybrid nanocomposite particles. The radioisotope nanocomposite particles prepared using the method can be used as diagnostic and therapeutic particles in the fields of oil refining, chemistry, cement, agriculture, water resources, environment, ocean, and medicine, and can also be used as a radioisotope tracer for evaluating the risk of nanomaterials.
Type:
Grant
Filed:
September 3, 2014
Date of Patent:
June 20, 2017
Assignee:
Korea Atomic Energy Research Institute
Inventors:
Sung-Hee Jung, Sun Ju Choi, Jong Bum Kim, Jin Ho Moon, Seong Ho Choi, Sang Ei Seo
Abstract: The present invention relates to the use of a combination of several contrast agents having different properties with respect to imaging representation.
Abstract: The present invention relates to a method for preparing a composition comprising nanoparticles of a noble metal functionalized with at least one type of metal complex and surfactant. The method comprises providing a first solution comprising nanoparticles and surfactant, and a second solution comprising a first type of metal complex, and adding the second solution to the first solution. Each nanoparticle has a loading of at least 500 and the method permits independent control of particle size and loading and enables large particles with high loading to be reproduced without agglomeration.
Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
Abstract: There is provided a contrast agent for photoacoustic imaging, the contrast agent exhibiting high tumor accumulation and high photoacoustic signal intensity even when time has passed since administration. A contrast agent for photoacoustic imaging comprises a complex including albumin covalently bound to an organic dye that absorbs light in the near-infrared wavelength region.
Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
Abstract: The disclosure provides, in part, fluorocarbon imaging reagents and methods for image-guided treatment and/or diagnosis of a subject with a condition associated with an inflammatory response in an internal organ. The disclosure additionally provides methods for image-guided treatment of myocardial infarction (MI) in a subject.
Type:
Grant
Filed:
September 17, 2013
Date of Patent:
May 16, 2017
Assignees:
University of Pittsburgh-of the Commonwealth System of Higher Education, Carnegie Mellon University
Abstract: A chelating system for inclusion in a composition at least stored in a polymer lined metal passivated steel container which provides for stability of both the composition and the container. The composition preferably is a cleaning composition including a color-changing dye or indicator. The chelating system provides for stable storage of the composition through preventing degradation of the dye/indicator over an extended storage time. The chelating system included in the composition has a low affinity for the passivation metal on the steel container which provides for stability of the polymer liner present over the passivation layer and, thus, provides for the stability of the container. A preferred combination is a cleaning composition including (a) tetrasodium iminodisuccinate as the chelant and (b) a pH sensitive color-changing dye/indicator, in combination with a PET-lined chromium passivated tin-free steel container.
Type:
Grant
Filed:
June 13, 2014
Date of Patent:
May 16, 2017
Assignee:
S. C. Johnson & Son, Inc.
Inventors:
Matthew M. Petkus, Rahul Saxena, Steven J. Suess, Stacey A. Verbeten
Abstract: The present disclosure relates to a medical device and methods of making the same. The medical device includes a porous substrate and at least one film. The film is formed within the pore of the substrate. The film is intra-porous and does not contact adjacent pores or films.
Type:
Grant
Filed:
August 25, 2015
Date of Patent:
May 9, 2017
Assignee:
Covidien LP
Inventors:
Joshua Stopek, Amin Elachchabi, Daniel Broom
Abstract: Methods are described and related devices, compositions, and systems, in which a caged compound is administered to a biological environment, the caged compound being caged with a long wavelength absorber, the long wavelength being a wavelength greater than or equal to 750 nm; and irradiating the biological environment to excite the long wavelength absorber with light at a wavelength in a range from 900-1100 nm, thus decaging the compound.
Type:
Grant
Filed:
December 7, 2012
Date of Patent:
May 2, 2017
Assignees:
CALIFORNIA INSTITUTE OF TECHNOLOGY, University of Southern California
Inventors:
Dennis A. Dougherty, Robert H. Grubbs, Mark Humayun, Clinton J. Regan, Azita Emami
Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.
Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.
Abstract: Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.
Abstract: Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.
Type:
Grant
Filed:
December 15, 2014
Date of Patent:
April 4, 2017
Assignee:
PROBIODRUG AG
Inventors:
Ulrich Heiser, Daniel Ramsbeck, Hans-Ulrich Demuth
Abstract: A water-soluble compound of the formula (I): wherein R9 and R10 are suitably hydrophilic substituents, which may be used to selectively bind to a target saccharide such as glucose and which exhibits a detectable spectroscopic response to such binding, thus enabling its use in the detection and correction of blood glucose concentrations in vivo.
Abstract: The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.
Abstract: The present invention relates to the synthesis and use of a novel trifluorinated bile acid analog, that being, CA-sar-TFMA which is useful as an imaging probe, diagnostic agent or contrast agent and is resistant to bacterial deconjugation, wherein the trifluorinated bile acid analog can be used as a 19F MRI tracer exhibiting an increased half-life due to its resistance to choloylglycine hydrolase.
Type:
Grant
Filed:
November 7, 2014
Date of Patent:
March 21, 2017
Assignee:
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMETN OF VETERANS AFFAIRS
Inventors:
James E. Polli, Jean-Pierre Raufman, Diana Vivian